Few drug classes have generated as much attention -- and confusion -- in Medicare as GLP-1 agonists: Ozempic, Wegovy, Mounjaro, and Zepbound. They belong to the same drug family, but Medicare treats them differently depending on the diagnosis they are prescribed for, not the brand name. This guide explains, for 2026, what Medicare can and cannot cover, why two drugs with the same active ingredient follow different rules, and what to check before assuming your plan will cover one.
The base rule: the diagnosis decides coverage, not the drug
By federal law, Medicare Part D cannot cover drugs prescribed solely for weight loss when that is the only diagnosis on file. However, the same active ingredients -- semaglutide and tirzepatide -- are also FDA-approved for other specific medical uses, and when a doctor documents one of those approved uses, the drug can be placed on a Medicare Advantage or stand-alone Part D plan's formulary.
In practice, this looks like: Ozempic and Mounjaro are approved for managing type 2 diabetes, so many plans cover them under that diagnosis. Wegovy is approved both for weight loss and for reducing the risk of serious cardiovascular events in people with obesity and already-diagnosed heart disease, and some plans cover it specifically under that second indication. Zepbound is approved for weight loss and also for moderate-to-severe obstructive sleep apnea in people with obesity, and coverage can depend on which of those two diagnoses supports the prescription.
Availability, cost, benefits, and eligibility vary by person, product, contract, and insurance company, as well as by your service area. Guarantees are subject to the claims-paying ability of the issuing insurance company. Karla Arámburo is not affiliated with or endorsed by Medicare or the federal government.
Why two people with the same prescription can have different coverage
It is common for two beneficiaries taking the same drug to have completely different coverage experiences, and the reason is almost always the diagnosis code the doctor submits to the plan, not the plan itself. If the medical record documents type 2 diabetes, established cardiovascular disease, or sleep apnea as applicable to the drug, the odds of coverage rise considerably. If the only diagnosis on file is obesity or overweight with none of those additional conditions, Part D is far more likely to deny coverage, regardless of how well-documented the overweight condition itself is.
Prior authorization: what the plan usually asks for
Nearly every plan requires prior authorization for GLP-1 drugs, given their high cost. It is common for them to ask for: the exact diagnosis with the corresponding code, recent related lab results (such as A1C for diabetes), evidence that other first-line treatments were tried before moving to a GLP-1, and in some cases, a minimum body mass index (BMI) along with an additional weight-related condition. Your doctor starts the process, but you can follow up on the request's status by calling your plan's customer service number.
Typical costs and the Part D $2,000 annual cap
| Situation | What you can expect to pay |
|---|---|
| Drug covered under an approved diagnosis | You pay the copay or coinsurance for the formulary tier the drug is placed on, until you reach the Part D annual out-of-pocket cap. |
| Drug not covered (weight loss only) | You pay the full list price, roughly $900 to $1,300 a month, unless you qualify for a manufacturer savings program. |
Starting in 2025, Part D has a $2,000 annual out-of-pocket cap on drugs covered by the plan. Once you reach that cap within the calendar year, the plan covers the rest of your covered drug costs, including a GLP-1 if it is on the formulary under an approved diagnosis. That cap does not apply if the drug was never covered due to lacking a qualifying diagnosis, so confirming coverage before starting treatment can mean a difference of thousands of dollars a year.
How to find out if your plan covers the drug you need
The first step is to review your specific plan's formulary -- not a generic plan from the same insurer -- looking for the exact drug name and confirming what tier it falls on and whether it requires prior authorization. The second step is to talk with your doctor about which diagnosis will support the prescription, since this determines whether the plan will even consider covering it. If you are comparing plans for next year and know you will need one of these drugs, check this before the Annual Enrollment Period rather than discovering it after you enroll. To understand the other add-on benefits worth comparing when choosing a plan, see our guides on the OTC and flex card benefit and dental, vision, and hearing benefits, and to understand Medicare's overall 2026 cost structure, review our 2026 Medicare costs guide.
Many of my clients across Southern California, including families in San Diego and Riverside, ask me if they can simply request the drug by its brand name. I explain that what actually determines coverage is the documented diagnosis, and I review with them how to raise it with their doctor before the appointment.
Free bilingual help understanding your GLP-1 drug coverage
I am Karla Arámburo, an independent, bilingual insurance agent licensed across Southern California. I review the formulary, coverage tier, and prior authorization rules of plans available in your ZIP code for the GLP-1 drug you need, in Spanish or English, at no cost to you.
You can call or text (619) 321-8733 or schedule a free consultation. This page is general education, not medical advice or a guarantee of coverage for a specific drug or plan.
Frequently asked questions
Does Medicare cover Ozempic, Wegovy, Mounjaro, or Zepbound?
It depends on the diagnosis, not just the drug's name. Part D generally cannot cover a drug prescribed solely for weight loss, but it can cover the same active ingredient when prescribed for an FDA-approved use, such as type 2 diabetes (Ozempic, Mounjaro), reducing cardiovascular risk in people with obesity and heart disease (Wegovy), or moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
If my plan covers Ozempic for diabetes, does it also cover Wegovy for weight loss?
Not automatically. They are different drugs with different approved indications, each sitting on its own formulary tier. Your plan covering one for diabetes does not mean it covers the other if the only reason for the prescription is weight loss alone.
What is prior authorization and why is it required for these drugs?
It is a process where your doctor must submit documentation to the plan explaining the diagnosis and sometimes prior treatments tried, before the plan approves covering the drug. Given the high cost and potential for off-label use of GLP-1s, nearly every plan requires this step before the prescription is filled.
How much do these drugs cost without coverage?
List price runs roughly $900 to $1,300 a month depending on the drug and dose, before any manufacturer discount or insurance coverage. That cost is why many beneficiaries check their plan's coverage before a doctor prescribes one of these medications.
Does the Part D annual out-of-pocket cap help with these drugs?
Yes, when the drug is covered under an approved diagnosis. Starting in 2025, Part D has a $2,000 annual out-of-pocket cap on covered drugs; once you hit it, the plan pays the rest of your covered drug costs for the remainder of the calendar year.
Can I switch plans mid-year if I need a GLP-1 medication?
Generally not, outside of a qualifying Special Enrollment Period. Plan changes for formulary reasons are usually made during the Annual Enrollment Period (October 15 through December 7), so it is worth reviewing these drugs' coverage before that date if you know you will need them next year.
Can you help me compare plans if I take or need a GLP-1 medication?
Yes. I review the formulary, tier placement, and prior authorization rules of plans available in your ZIP code for the specific drug and dose you need, along with your doctor network, at no cost to you.
Related guides
Written by Karla Arámburo, licensed California insurance agent (License #4431554, NPN 21399485)
